These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

270 related articles for article (PubMed ID: 17307170)

  • 1. A randomized, controlled trial of asoprisnil, a novel selective progesterone receptor modulator, in women with uterine leiomyomata.
    Chwalisz K; Larsen L; Mattia-Goldberg C; Edmonds A; Elger W; Winkel CA
    Fertil Steril; 2007 Jun; 87(6):1399-412. PubMed ID: 17307170
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Therapeutic potential for the selective progesterone receptor modulator asoprisnil in the treatment of leiomyomata.
    Chwalisz K; DeManno D; Garg R; Larsen L; Mattia-Goldberg C; Stickler T
    Semin Reprod Med; 2004 May; 22(2):113-9. PubMed ID: 15164306
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Safety and efficacy of the selective progesterone receptor modulator asoprisnil for heavy menstrual bleeding with uterine fibroids: pooled analysis of two 12-month, placebo-controlled, randomized trials.
    Stewart EA; Diamond MP; Williams ARW; Carr BR; Myers ER; Feldman RA; Elger W; Mattia-Goldberg C; Schwefel BM; Chwalisz K
    Hum Reprod; 2019 Apr; 34(4):623-634. PubMed ID: 30865281
    [TBL] [Abstract][Full Text] [Related]  

  • 4. The effects of the selective progesterone receptor modulator asoprisnil on the morphology of uterine tissues after 3 months treatment in patients with symptomatic uterine leiomyomata.
    Williams AR; Critchley HO; Osei J; Ingamells S; Cameron IT; Han C; Chwalisz K
    Hum Reprod; 2007 Jun; 22(6):1696-704. PubMed ID: 17339234
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Effects of the selective progesterone receptor modulator asoprisnil on uterine artery blood flow, ovarian activity, and clinical symptoms in patients with uterine leiomyomata scheduled for hysterectomy.
    Wilkens J; Chwalisz K; Han C; Walker J; Cameron IT; Ingamells S; Lawrence AC; Lumsden MA; Hapangama D; Williams AR; Critchley HO
    J Clin Endocrinol Metab; 2008 Dec; 93(12):4664-71. PubMed ID: 18765509
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Cell-type specific actions of progesterone receptor modulators in the regulation of uterine leiomyoma growth.
    Yoshida S; Ohara N; Xu Q; Chen W; Wang J; Nakabayashi K; Sasaki H; Morikawa A; Maruo T
    Semin Reprod Med; 2010 May; 28(3):260-73. PubMed ID: 20414849
    [TBL] [Abstract][Full Text] [Related]  

  • 7. The effects of 1-month administration of asoprisnil (J867), a selective progesterone receptor modulator, in healthy premenopausal women.
    Chwalisz K; Elger W; Stickler T; Mattia-Goldberg C; Larsen L
    Hum Reprod; 2005 Apr; 20(4):1090-9. PubMed ID: 15665012
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Selective progesterone receptor modulator development and use in the treatment of leiomyomata and endometriosis.
    Chwalisz K; Perez MC; Demanno D; Winkel C; Schubert G; Elger W
    Endocr Rev; 2005 May; 26(3):423-38. PubMed ID: 15857972
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Selective progesterone receptor modulator asoprisnil down-regulates collagen synthesis in cultured human uterine leiomyoma cells through up-regulating extracellular matrix metalloproteinase inducer.
    Morikawa A; Ohara N; Xu Q; Nakabayashi K; DeManno DA; Chwalisz K; Yoshida S; Maruo T
    Hum Reprod; 2008 Apr; 23(4):944-51. PubMed ID: 18281245
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Selective progesterone receptor modulator asoprisnil induces endoplasmic reticulum stress in cultured human uterine leiomyoma cells.
    Xu Q; Ohara N; Liu J; Nakabayashi K; DeManno D; Chwalisz K; Yoshida S; Maruo T
    Am J Physiol Endocrinol Metab; 2007 Oct; 293(4):E1002-11. PubMed ID: 17652152
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Goserelin acetate 10.8 mg plus iron versus iron monotherapy prior to surgery in premenopausal women with iron-deficiency anemia due to uterine leiomyomas: results from a Phase III, randomized, multicenter, double-blind, controlled trial.
    Muneyyirci-Delale O; Richard-Davis G; Morris T; Armstrong J
    Clin Ther; 2007 Aug; 29(8):1682-91. PubMed ID: 17919549
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Molecule of the month: asoprisnil.
    Drug News Perspect; 2005; 18(6):404. PubMed ID: 16247518
    [No Abstract]   [Full Text] [Related]  

  • 13. A novel selective progesterone receptor modulator asoprisnil (J867) down-regulates the expression of EGF, IGF-I, TGFbeta3 and their receptors in cultured uterine leiomyoma cells.
    Wang J; Ohara N; Wang Z; Chen W; Morikawa A; Sasaki H; DeManno DA; Chwalisz K; Maruo T
    Hum Reprod; 2006 Jul; 21(7):1869-77. PubMed ID: 16613890
    [TBL] [Abstract][Full Text] [Related]  

  • 14. A novel selective progesterone receptor modulator asoprisnil (J867) inhibits proliferation and induces apoptosis in cultured human uterine leiomyoma cells in the absence of comparable effects on myometrial cells.
    Chen W; Ohara N; Wang J; Xu Q; Liu J; Morikawa A; Sasaki H; Yoshida S; Demanno DA; Chwalisz K; Maruo T
    J Clin Endocrinol Metab; 2006 Apr; 91(4):1296-304. PubMed ID: 16464945
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Low-dose mifepristone in treatment of uterine leiomyoma: a randomised double-blind placebo-controlled clinical trial.
    Bagaria M; Suneja A; Vaid NB; Guleria K; Mishra K
    Aust N Z J Obstet Gynaecol; 2009 Feb; 49(1):77-83. PubMed ID: 19281585
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Uterine NK cells regulate endometrial bleeding in women and are suppressed by the progesterone receptor modulator asoprisnil.
    Wilkens J; Male V; Ghazal P; Forster T; Gibson DA; Williams AR; Brito-Mutunayagam SL; Craigon M; Lourenco P; Cameron IT; Chwalisz K; Moffett A; Critchley HO
    J Immunol; 2013 Sep; 191(5):2226-35. PubMed ID: 23913972
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Effect of asoprisnil on uterine proliferation markers and endometrial expression of the tumour suppressor gene, PTEN.
    Wilkens J; Williams AR; Chwalisz K; Han C; Cameron IT; Critchley HO
    Hum Reprod; 2009 May; 24(5):1036-44. PubMed ID: 19176543
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Mifepristone for treatment of uterine leiomyoma. A prospective randomized placebo controlled trial.
    Engman M; Granberg S; Williams AR; Meng CX; Lalitkumar PG; Gemzell-Danielsson K
    Hum Reprod; 2009 Aug; 24(8):1870-9. PubMed ID: 19389793
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Treatment of leiomyomata uteri with leuprolide acetate depot: a double-blind, placebo-controlled, multicenter study. The Leuprolide Study Group.
    Friedman AJ; Hoffman DI; Comite F; Browneller RW; Miller JD
    Obstet Gynecol; 1991 May; 77(5):720-5. PubMed ID: 1901638
    [TBL] [Abstract][Full Text] [Related]  

  • 20. A placebo-controlled trial of a depot gonadotropin-releasing hormone analogue (leuprolide) in the treatment of uterine leiomyomata.
    Schlaff WD; Zerhouni EA; Huth JA; Chen J; Damewood MD; Rock JA
    Obstet Gynecol; 1989 Dec; 74(6):856-62. PubMed ID: 2511532
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 14.